Current treatment strategies for clozapine-induced sialorrhea;Un repaso de las estrategias de tratamiento actuales de la sialorrea inducida por clozapina

Annals of Pharmacotherapy

Volumn 45, Issue 5, 2011, Pages 667-675

  Bird, Angela M ^a   Smith, Tawny L ^b   Walton, Amy E ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Clozapine; Hypersalivation; Sialorrhea

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMISULPRIDE; AMITRIPTYLINE; ATROPINE; BENZAMIDE DERIVATIVE; BENZATROPINE; BIPERIDEN; BOTULINUM TOXIN; CLONIDINE; CLOZAPINE; GLYCOPYRRONIUM BROMIDE; GUANFACINE; IPRATROPIUM BROMIDE; MOCLOBEMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; PIRENZEPINE; PLACEBO; RISPERIDONE; SCOPOLAMINE; SULPIRIDE; TERAZOSIN; TOLTERODINE; TRIHEXYPHENIDYL;

ANXIETY DISORDER; ARTICLE; BEDTIME DOSAGE; BLURRED VISION; BRADYCARDIA; CEREBRAL PALSY; CLINICAL TRIAL (TOPIC); CLOZAPINE INDUCED SIALORRHEA; COMBINATION CHEMOTHERAPY; CONFUSION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPERSALIVATION; HYPERTENSION; MONOTHERAPY; MORNING DOSAGE; MOTION SICKNESS; NEUROLOGIC DISEASE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; XEROSTOMIA;

ADRENERGIC ALPHA-AGONISTS; CLINICAL TRIALS AS TOPIC; CLOZAPINE; DOUBLE-BLIND METHOD; HUMANS; MUSCARINIC ANTAGONISTS; RETROSPECTIVE STUDIES; SIALORRHEA;

EID: 79957614960     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P761     Document Type: Article

References (41)

1. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 198s8;45:789-96.
2. Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006;32:715-23. DOI 10.1093/schbul/sbj067
3. Product information. Clozaril (clozapine). East Hanover, NJ: Novartis Pharmaceuticals, revised January 2010.
4. Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 2003;15:33-48. DOI 10.3109/10401230309085668
5. Ben-Aryeh H, Jungerman T, Szargel R, Klein E, Laufer D. Salivary flow-rate and composition in schizophrenic patients on clozapine: subjective reports and laboratory data. Biol Psychiatry 1996;39:946-9. DOI 10.1016/0006-3223(95)00296-0
6. Reinstein MJ, Sirotovskaya LA, Chasanov MA, Jones LE, Mohan S. Comparative efficacy and tolerability of benzatropine and terazosin in the treatment of hypersalivation secondary to clozapine. Clin Drug Invest 1999;17:97-102. DOI 10.2165/00044011-199917020-00003
7. Liang CS, Ho PS, Shen LJ, Lee WK, Yang FW, Chiang KT. Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. Schizophr Res 2010;119:138-44. DOI 10.1016/j.schres.2010.02.1060
8. Zorn SH, Jones SB, Ward KM, Liston DR. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol 1994;269:R1-2. DOI 10.1016/0922-4106(94)90047-7
9. Grabowski J. Clonidine treatment of clozapine-induced hypersalivation (letter). J Clin Psychopharmacol 1992;12:69-70. DOI 10.1097/00004714-199202000-00026
10. Freudenreich O, Beebe M, Goff DC. Clozapine-induced sialorrhea treated with sublingual ipratropium spray: a case series (letter). J Clin Psychopharmacol 2004;24:98-100.
11. Spivak B, Adlersberg S, Rosen L, Gonen N, Mester R, Weizman A. Trihexyphenidyl treatment of clozapine induced hypersalivation (abstract). Int Clin Psychopharmacol 1997;12:213-5. DOI 10.1097/00004850-199707000-00005
12. Bai YM, Lin CC, Chen JY, Liu WC. Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Psychopharmacol 2001;21: 608-11.
13. Schneider B, Weigmann H, Hiemke C, Weber B, Fritze J. Reduction of clozapine-induced hypersalivation by pirenzepine is safe. Pharmacopsychiatry 2004;37:43-5.
14. Sockalingam S, Shammi C, Remington G. Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, doubleblind, placebo-controlled crossover study. J Clin Psychiatry 2009;70: 1114-9.
15. Praharaj SK, Verma P, Roy D, Singh A. Is clonidine useful for treatment of clozapine-induced sialorrhea? J Psychopharmacol 2005;19:426-8. DOI 10.1177/0269881105053311
16. Kreinin A, Epshtein S, Sheinkman A, Tell E. Sulpiride addition for the treatment of clozapine-induced hypersalivation: preliminary study. Isr J Psychiatry Relat Sci 2005;42:61-3.
17. Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapineinduced hypersalivation in schizophrenia patients: a randomized, doubleblind, placebo-controlled cross-over study. Int Clin Psychopharmacol 2006;21:99-103. DOI 10.1097/01.yic.0000188216.92408.69
18. Kreinin A, Miodownik C, Libov I, Shestakova D, Lerner V. Moclobemide treatment of clozapine-induced hypersalivation: pilot open study. Clin Neuropharm 2009;32:151-3
19. Kreinin A, Miodownik C, Sokolik S, et al. Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation (abstract). World J Biol Psychiatry 2010 Oct 21. [Epub ahead of print]
20. Steinlechner S, Klein C, Moser A, Lencer R, Hagenah J. Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea. Psychopharmacology 2010;207:593-7. DOI 10.1007/s00213-009-1689-y
21. Copp PJ, Lament R, Tennent TG. Amitriptyline in clozapine-induced sialorrhoea (letter). Br J Psychiatry 1991;159:166. DOI 10.1192/bjp.159.1.166a
22. Praharaj SK, Arora M. Amitriptyline for clozapine-induced nocturnal enuresis and sialorrhea (letter). Br J Clin Pharmacol 2007;63:128-9. DOI 10.1111/j.1365-2125.2006.02748.x
23. Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M. Treatment of sialorrhea with glycopyrrolate: a double-blind, dose-ranging study. Arch Pediatr Adolesc Med 2000;154:1214-8.
24. Fritze J, Elliger T. Pirenzepine for clozapine-induced hypersalivation (letter). Lancet 1995;346:1034. DOI 10.1016/S0140-6736(95)91713-6
25. Antonello C, Tessier P. Clozapine and sialorrhea: a new intervention for this bothersome and potentially dangerous side effect (letter). J Psychiatry Neurosci 1999;24:250.
26. Sharma A, Ramaswamy S, Dahl E, Dewan V. Intraoral application of atropine sulfate ophthalmic solution for clozapine-induced sialorrhea (letter). Ann Pharmacother 2004;38:1538. DOI 10.1345/aph.1E077
27. Tessier P, Antonello C. Clozapine and sialorrhea: update (letter). J Psychiatry Neurosci 2001;26:253.
28. Calderon J, Rubin E, Sobota WL. Potential use of ipratropium bromide for the treatment of clozapine-induced hypersalivation: a preliminary report. Int Clin Psychopharmacol 2000;15:49-52. DOI 10.1097/00004850-200015010-00008
29. Product information. Transderm Scop (scopolamine). Parsippany, NJ: Novartis Consumer Health, revised February 2006.
30. McKane JP, Hall C, Akram G. Hyoscine patches in clozapine-induced hypersalivation (letter). Psychiatr Bull 2001;25:277. DOI 10.1192/pb.25.7.277-c
31. Gaftanyuk O, Trestman RL. Scopolamine patch for clozapine-induced sialorrhea (letter). Psychiatr Serv 2004;55:318. DOI 10.1176/appi.ps.55.3.318
32. Product information. Catapres-TTS (clonidine). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, revised May 2010.
33. Webber MA, Szwast SJ, Steadman TM, et al. Guanfacine treatment of clozapine-induced sialorrhea (letter). J Clin Psychopharmacol 2004;24: 675-6. DOI 10.1097/01.jcp.0000145348.06783.1d
34. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A doubleblind, placebo-controlled study. Br J Psychiatry 1997;171:569-73.
35. Praharaj SK, Sarkar S, Sinha VK. Amisulpride treatment for clozapineinduced sialorrhea (letter). J Clin Psychopharmacol 2009;29:189-90. DOI 10.1097/JCP.0b013e318199f264
36. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Longlasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol 2009;256:563-7. DOI 10.1007/s00415-009-0085-1
37. Reid SM, Johnstone BR, Westbury C, Rawicki B, Reddihough DS. Randomized trial of botulinum toxin injections into the salivary glands reduce drooling in children with neurological disorders. Dev Med Child Neurol 2008;50:123-8. DOI 10.1111/j.1469-8749.2007.02015.x
38. Scheffer AR, Erasmus C, van Hulst K, van Limbeek J, Jongerius PH, van den Hoogen FJ. Efficacy and duration of botulinum toxin treatment for drooling in 131 children. Arch Otolaryngol Head Neck Surg 2010; 136:873-7. DOI 10.1001/archoto.2010.147
39. Kahl KG, Hagenah J, Zapf S, Trillenberg P, Klein C, Lencer R. Botulinum toxin as an effective treatment of clozapine-induced hypersalivation (letter). Psychopharmacology 2004;173:229-30. DOI 10.1007/s00213-004-1803-0
40. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003;61: 1279-81.
41. Syed R, Au K, Cahill C, et al. Pharmacologic interventions for clozapine-induced hypersalivation (review). Cochrane Database Syst Rev 2008;3:CD005579.